Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma

OBJECTIVE: A combination of bortezomib, cyclophosphamide, and dexamethasone is highly effective in the treatment of newly diagnosed multiple myeloma. Neuropathy is a dose-limiting adverse effect of this regimen. Subcutaneous and weekly injection instead of biweekly intravenous administration are use...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashrafi, Farzaneh, Moghaddas, Azadeh, Darakhshandeh, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235451/
https://www.ncbi.nlm.nih.gov/pubmed/32489962
http://dx.doi.org/10.4103/jrpp.JRPP_18_82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235451/
https://www.ncbi.nlm.nih.gov/pubmed/32489962
http://dx.doi.org/10.4103/jrpp.JRPP_18_82

Ejemplares similares